Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2019 08:19 ET | Source: Emergent BioSolutions

Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate

GAITHERSBURG, Md., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and...
November 21, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day

GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and...
November 18, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Host 2019 Analyst and Investor Day

GAITHERSBURG, Md., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in New...
November 06, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019

Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial...
October 21, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Host 2019 Analyst & Investor Day

GAITHERSBURG, Md., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New York...
October 10, 2019 06:38 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate

GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate,...
October 09, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019

GAITHERSBURG, Md., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the...
September 27, 2019 06:35 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder

GAITHERSBURG, Md., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of...
September 26, 2019 09:27 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference

GAITHERSBURG, Md., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor...
September 25, 2019 16:15 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense

GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an...